Loading…
Geron Corporation is projected to rise to $1.35 by 2027, a +7% move from its current price of $1.26. GERN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.22 | $1.26 | $1.30 | -0.01% |
| May 30 | $1.21 | $1.26 | $1.31 | -0.02% |
| May 31 | $1.20 | $1.26 | $1.33 | -0.04% |
| Jun 1 | $1.19 | $1.26 | $1.34 | -0.05% |
| Jun 2 | $1.18 | $1.26 | $1.35 | -0.06% |
| Jun 3 | $1.17 | $1.26 | $1.35 | -0.07% |
| Jun 4 | $1.16 | $1.26 | $1.36 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.16 | $1.26 | $1.36 | -0.08% |
| Week 2 | $1.13 | $1.26 | $1.41 | -0.17% |
| Week 3 | $1.10 | $1.26 | $1.44 | -0.25% |
| Week 4 | $1.07 | $1.26 | $1.47 | -0.34% |
| Week 5 | $1.05 | $1.25 | $1.50 | -0.42% |
| Week 6 | $1.03 | $1.25 | $1.52 | -0.50% |
| Week 7 | $1.02 | $1.25 | $1.54 | -0.59% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. Its product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation (GERN) is trading with a current price of $1.28 and a market capitalization of $821.15M, ranking 2671. The current price sits within a forecast that outlines a long-run trajectory with multiple years of growth potential.
A major floor 27.0% below — a decisive break under it would weaken the trend.
The nearest floor, 3.2% below — buyers have tended to step in here.
The nearest ceiling, 34.1% above — a clean break opens room to run.
A major ceiling 54.8% above — clearing it would confirm fresh momentum.
Key GERN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GERN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.27 | Sell | $1.27 | Sell |
| MA 10 | $1.29 | Sell | $1.30 | Sell |
| MA 20 | $1.40 | Sell | $1.37 | Sell |
| MA 50 | $1.52 | Sell | $1.46 | Sell |
| MA 100 | $1.52 | Sell | $1.48 | Sell |
| MA 200 | $1.41 | Sell | $1.54 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 34.27 | Neutral |
| Stoch RSI (14) | 44.45 | Neutral |
| CCI (20) | -82.14 | Neutral |
| Williams %R (14) | -83.33 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -9.35 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 16.67 | Buy |
| TRIX (15) | -0.73 | Sell |
| Awesome (5,34) | -0.22 | Sell |
| Ultimate (7,14,28) | 31.84 | Neutral |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 1.27 | Sell |
| ADX (14) | 23.13 | Sell |
| ATR (14) | 0.04 | Info |
Technically, the picture is NEUTRAL with RSI14 at 40. The 50-day simple moving average is $1.53 and the 200-day simple moving average is $1.41. Key near-term levels are support at $1.22 and resistance at $1.77.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.22 | $1.26 | $1.69 | 0% | Neutral | |
| $1.06 | $1.35 | $1.82 | +7% | Neutral | |
| $1.05 | $1.38 | $1.93 | +9% | Neutral | |
| $1.12 | $1.50 | $2.17 | +19% | Neutral | |
| $1.32 | $1.81 | $2.68 | +44% | Bullish | |
| $1.52 | $2.13 | $3.23 | +69% | Bullish | |
| $1.51 | $2.16 | $3.34 | +71% | Bullish | |
| $1.51 | $2.19 | $3.46 | +74% | Bullish | |
| $1.53 | $2.26 | $3.62 | +79% | Bullish | |
| $1.55 | $2.33 | $3.79 | +85% | Bullish | |
| $2.08 | $3.37 | $5.86 | +168% | Bullish | |
| $4.02 | $7.41 | $14.16 | +488% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.22 | $1.26 | $1.49 | +0.00% |
| June 2026 | $1.09 | $1.28 | $1.55 | +1.73% |
| July 2026 | $1.05 | $1.25 | $1.52 | -2.78% |
| August 2026 | $1.04 | $1.25 | $1.54 | +0.18% |
| September 2026 | $1.07 | $1.29 | $1.61 | +3.12% |
| October 2026 | $1.06 | $1.28 | $1.62 | -0.28% |
| November 2026 | $1.05 | $1.27 | $1.61 | -0.86% |
| December 2026 | $1.08 | $1.32 | $1.69 | +4.00% |
Click any year to see its month-by-month GERN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, GERN is projected to trade between $1.22 and $1.69, averaging $1.26 — a potential gain of 0% from today's $1.26. A consolidation phase looks the most probable path here.
Geron Corporation's 2027 outlook centres on $1.35, within a $1.06 to $1.82 range. That is up +7% on the projected 2026 average. That marks a +7% change versus current levels. Price action looks broadly range-bound.
By 2028, GERN could reach as high as $1.93, with a base case around $1.38 and support toward $1.05 — roughly +9% from $1.26. A consolidation phase looks the most probable path here.
Expect GERN to range from $1.12 to $2.17 through 2029. The $1.50 average target implies a +19% move from current prices. That is up +9% on the projected 2028 average. Price action looks broadly range-bound.
The GERN price prediction for 2030 points to an average of $1.81 (low $1.32, high $2.68) — a potential gain of +44% on today's $1.26. Buyers look set to stay in control over this stretch.
In 2031, GERN is projected to trade between $1.52 and $3.23, averaging $2.13 — a potential gain of +69% from today's $1.26. That is up +18% on the projected 2030 average. Momentum favours further upside here.
Geron Corporation's 2032 outlook centres on $2.16, within a $1.51 to $3.34 range. That is up +2% on the projected 2031 average. That marks a +71% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, GERN could reach as high as $3.46, with a base case around $2.19 and support toward $1.51 — roughly +74% from $1.26. Momentum favours further upside here.
Expect GERN to range from $1.53 to $3.62 through 2034. The $2.26 average target implies a +79% move from current prices. That is up +3% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The GERN price prediction for 2035 points to an average of $2.33 (low $1.55, high $3.79) — a potential gain of +85% on today's $1.26. Momentum favours further upside here.
In 2040, GERN is projected to trade between $2.08 and $5.86, averaging $3.37 — a potential gain of +168% from today's $1.26. That is up +45% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Geron Corporation's 2050 outlook centres on $7.41, within a $4.02 to $14.16 range. That is up +120% on the projected 2040 average. That marks a +488% change versus current levels. Momentum favours further upside here.
Investing $1,000 in GERN today (≈ 793.650794 GERN) could be worth
$5,884.34
+$4,884.34 (+488%) by 2050 · US Dollar
Based on the average projected GERN price of $7.41 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GERNwould be worth at today's price.
$1,000 invested in GERN on May 27, 2025 (≈ 671.140935 GERN) would be worth
$845.64
-$154.36 (-15.4%) today · 0.85× · US Dollar
Based on a GERN entry price of $1.49 vs. today's $1.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.26 | $1,000 | +0.0% |
| 1 month ago | $1.53 | $823.53 | -17.6% |
| 3 months ago | $1.65 | $763.64 | -23.6% |
| 6 months ago | $1.18 | $1,067.8 | +6.8% |
| 1 year ago | $1.49 | $845.64 | -15.4% |
| All time (5.0y) ago | $1.4 | $900 | -10.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GERN forecast.
Our base-case forecast reaches $2.50 around 2040.
Implied market cap at $2.50: $1.6B
The multi-year forecast shows a bullish trend emerging from 2030 onward. The 2030 average price is $1.84 with an ROI of 43.9% and a bullish sentiment. By 2040 the average price is projected at $3.42 with an ROI of 167.5%.
By 2050 the average price is $7.68 with an ROI of 499.9%, indicating substantial upside over the longer horizon. The forecast for 2026 shows an average price of $1.28 with an ROI of 0% and a neutral sentiment, transitioning to stronger upside in the following years. These figures are estimates and are not guarantees, reflecting varying degrees of market uncertainty over time.
Tap a question to reveal the answer.
2030 average price is $1.84 with an ROI of 43.9% (sentiment: BULLISH).
The forecast begins neutral in 2026 and turns bullish from 2030 onward, with 2030 avg $1.84 and 2050 avg $7.68, and ROI rising to 499.9% by 2050, indicating substantial long‑term upside while acknowledging short‑term uncertainty.
The max prices in the forecast reach $6.07 in 2040 and $15.00 in 2050, so a $5 level is within the forecast by 2040.
$821.15M.
Geron Corporation Community Discussion
0Share your Geron Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.